Correlation Between Equillium and Crispr Therapeutics

Can any of the company-specific risk be diversified away by investing in both Equillium and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Equillium and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Equillium and Crispr Therapeutics AG, you can compare the effects of market volatilities on Equillium and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Equillium with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Equillium and Crispr Therapeutics.

Diversification Opportunities for Equillium and Crispr Therapeutics

0.87

Correlation Coefficient

Equillium  Crispr Therapeutics

Very poor diversification

The 3 months correlation between Equillium and Crispr is 0.87. Overlapping area represents the amount of risk that can be diversified away by holding Equillium and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Equillium is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Equillium are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Equillium i.e., Equillium and Crispr Therapeutics go up and down completely randomly.

Pair Corralation between Equillium and Crispr Therapeutics

Allowing for the 90-day total investment horizon Equillium is expected to under-perform the Crispr Therapeutics. In addition to that, Equillium is 1.78 times more volatile than Crispr Therapeutics AG. It trades about -0.15 of its total potential returns per unit of risk. Crispr Therapeutics AG is currently generating about -0.18 per unit of volatility. If you would invest  6,818  in Crispr Therapeutics AG on February 28, 2024 and sell it today you would lose (1,334) from holding Crispr Therapeutics AG or give up 19.57% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Equillium  vs.  Crispr Therapeutics AG

Equillium

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Equillium has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in June 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Crispr Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Crispr Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in June 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Equillium and Crispr Therapeutics

The main advantage of trading using opposite Equillium and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Equillium position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.

The idea behind Equillium and Crispr Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.